Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8541971 | 0.89 | APEX1 (0.75) | APEX1POLBGPBAR1TSHRHSD17B10 | |
| SCHEMBL8544209 | 0.89 | APEX1 (0.75) | APEX1POLBGPBAR1TSHRHSD17B10 | |
| SCHEMBL1001249 | 0.88 | APEX1 (0.73) | APEX1POLBKMT2AGPBAR1TSHR | |
| SCHEMBL4551788 | 0.86 | POLB (0.60) | APEX1POLBKMT2AMEN1KDM4E | |
| SCHEMBL8540145 | 0.86 | APEX1 (0.70) | APEX1L3MBTL1POLBKMT2AMEN1 | |
| SCHEMBL8540322 | 0.86 | POLB (0.73) | APEX1POLBKMT2AMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL6196657 | 0.85 | POLB (0.61) | APEX1POLBKMT2AMEN1KDM4E | |
| SCHEMBL28653785 | 0.84 | HSD17B10 (0.77) | L3MBTL1POLBKMT2AKDM4ETSHR | |
| SCHEMBL1647757 | 0.82 | POLB (0.88) | L3MBTL1POLBKMT2AKDM4ETSHR | |
| SCHEMBL396705 | 0.82 | KMT2A (0.77) | L3MBTL1POLBKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305250-B1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-03-26 | — | — | EP | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| EP-1648426-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| EP-0994115-B1 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | PFIZER LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2003-04-10 | — | — | US | disclosed |
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2001-07-26 | — | — | US | disclosed |
| US-6207829-B1 | CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0994115-A2 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | APEX1 4585/4885L3MBTL1 3063/4885POLB 612/4885 |
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | APEX1 1440/4885L3MBTL1 4245/4885POLB 66/4885 |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | APEX1 4585/4885L3MBTL1 3063/4885POLB 612/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | APEX1 4403/4885L3MBTL1 2624/4885POLB 672/4885 |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | APEX1 1440/4885L3MBTL1 4245/4885POLB 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.